ATE508190T1 - Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien - Google Patents
Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentienInfo
- Publication number
- ATE508190T1 ATE508190T1 AT05727680T AT05727680T ATE508190T1 AT E508190 T1 ATE508190 T1 AT E508190T1 AT 05727680 T AT05727680 T AT 05727680T AT 05727680 T AT05727680 T AT 05727680T AT E508190 T1 ATE508190 T1 AT E508190T1
- Authority
- AT
- Austria
- Prior art keywords
- expression cassettes
- simultaneous delivery
- rnai agent
- multiple promotor
- promotor expression
- Prior art date
Links
- 108091030071 RNAI Proteins 0.000 title abstract 2
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55050404P | 2004-03-05 | 2004-03-05 | |
| US55392004P | 2004-03-17 | 2004-03-17 | |
| PCT/US2005/007447 WO2005087926A2 (en) | 2004-03-05 | 2005-03-04 | Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE508190T1 true ATE508190T1 (de) | 2011-05-15 |
Family
ID=34963938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05727680T ATE508190T1 (de) | 2004-03-05 | 2005-03-04 | Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7727970B2 (de) |
| EP (2) | EP1725660B1 (de) |
| JP (1) | JP4763681B2 (de) |
| KR (2) | KR101246862B1 (de) |
| CN (1) | CN103060324B (de) |
| AT (1) | ATE508190T1 (de) |
| AU (1) | AU2005222084B2 (de) |
| CA (1) | CA2558771C (de) |
| DE (1) | DE602005027820D1 (de) |
| DK (1) | DK1725660T3 (de) |
| IL (1) | IL177862A (de) |
| NZ (1) | NZ550284A (de) |
| WO (1) | WO2005087926A2 (de) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101246862B1 (ko) * | 2004-03-05 | 2013-03-27 | 베니텍 리미티드 | ＲＮＡｉ 제제의 동시 전달을 위한 다중 프로모터 발현카세트 |
| EP2772541A3 (de) | 2004-09-24 | 2014-09-24 | Alnylam Pharmaceuticals Inc. | Targeting von Zwischenprodukten zur Gegenstrangreplikation von Hepatitis C Virus durch RNAi |
| EP2189469B1 (de) * | 2004-11-18 | 2015-09-16 | The Board Of Trustees Of The University Of Illinois | Multicistronische siRNA-Konstrukte zur Hemmung von Tumoren |
| CN101180394B (zh) * | 2005-02-03 | 2013-01-09 | 贝尼泰克有限公司 | RNAi表达构建体 |
| CA2606002A1 (en) * | 2005-04-28 | 2006-11-02 | Benitec Limited | Multiple-rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns |
| US7452696B2 (en) * | 2006-10-27 | 2008-11-18 | National Taiwan University | Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo |
| WO2008069940A2 (en) * | 2006-12-06 | 2008-06-12 | Albert Einstein College Of Medicine Of Yeshiva University | Multi-microrna methods and compositions |
| US20100263066A1 (en) * | 2007-04-30 | 2010-10-14 | Medtronic, Inc | Inert dna sequences for efficient viral packaging and methods of use |
| WO2009002918A2 (en) | 2007-06-22 | 2008-12-31 | Nucleonics, Inc. | Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| US20100040546A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| US20120034155A1 (en) * | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
| US20100041133A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| US20100042072A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| US9272053B2 (en) | 2010-04-23 | 2016-03-01 | University Of Massachusetts | AAV-based treatment of cholesterol-related disorders |
| CA2833905C (en) * | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
| EP3567106A1 (de) | 2010-04-23 | 2019-11-13 | University of Massachusetts | Auf das zns abzielende aav-vektoren und verfahren zur verwendung davon |
| PT3124610T (pt) | 2010-10-28 | 2019-06-14 | Benitec Biopharma Ltd | Tratamento do vhb |
| KR101554678B1 (ko) * | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
| JP2016507514A (ja) * | 2013-01-08 | 2016-03-10 | ベニテック バイオファーマ リミテッド | 加齢黄斑変性の処置 |
| CA3276269A1 (en) | 2014-03-18 | 2026-03-02 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
| GB201405834D0 (en) * | 2014-04-01 | 2014-05-14 | Univ London Queen Mary | Oncolytic virus |
| WO2015187825A2 (en) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| EP3200830B1 (de) | 2014-10-03 | 2020-09-09 | University of Massachusetts | Hocheffiziente bibliotheksidentifizierte aav-vektoren |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| RU2020140209A (ru) | 2014-10-21 | 2021-01-25 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
| IL292999A (en) | 2014-11-14 | 2022-07-01 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN112410338A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| EP3221445B1 (de) | 2014-11-20 | 2021-07-14 | The Regents of The University of California | Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung |
| WO2016131009A1 (en) | 2015-02-13 | 2016-08-18 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
| US11046955B2 (en) | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
| WO2017070525A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
| EP3364996B1 (de) | 2015-10-22 | 2021-08-25 | University of Massachusetts | Gegen die prostata gerichtete adeno-assoziierte virusserotypvektoren |
| EP3377630A4 (de) | 2015-11-16 | 2020-01-01 | Olix Pharmaceuticals, Inc. | Behandlung von altersbedingter makuladegeneration mit auf myd88 oder tlr3 abzielenden rna-komplexen |
| WO2017136536A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 |
| WO2017139643A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| WO2017176929A1 (en) | 2016-04-05 | 2017-10-12 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| WO2017181105A1 (en) | 2016-04-15 | 2017-10-19 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| US11882815B2 (en) | 2016-06-15 | 2024-01-30 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| WO2018017814A1 (en) | 2016-07-20 | 2018-01-25 | President And Fellows Of Harvard College | Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections |
| US11202818B2 (en) | 2016-09-14 | 2021-12-21 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| CA3040483A1 (en) | 2016-10-13 | 2018-04-19 | University Of Massachusetts | Aav capsid designs |
| WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
| WO2018112364A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| WO2018112365A2 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii |
| WO2018112363A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Methods of treating cancer using parabacteroides |
| WO2018112360A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| EP3570856A2 (de) | 2017-01-18 | 2019-11-27 | Evelo Biosciences, Inc. | Verfahren zur behandlung von krebs |
| EP3570857A1 (de) | 2017-01-18 | 2019-11-27 | Evelo Biosciences, Inc. | Verfahren zur behandlung von krebs |
| SG11201909870SA (en) * | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| EP3622073A4 (de) | 2017-05-09 | 2021-01-06 | University of Massachusetts | Verfahren zur behandlung von amyotropher lateralsklerose (als) |
| US11241461B2 (en) | 2017-08-29 | 2022-02-08 | Evelo Biosciences, Inc. | Treating cancer using a blautia strain |
| US11739330B2 (en) | 2017-09-22 | 2023-08-29 | University Of Massachusetts | SOD1 dual expression vectors and uses thereof |
| US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
| EP4454654A3 (de) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Behandlung von amyotropher lateralsklerose (als) |
| WO2019169138A1 (en) | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using paraclostridium benzoelyticum |
| WO2019169160A1 (en) | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using ruminococcus gnavus |
| WO2019169143A1 (en) | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using turicibacter sanguinis |
| WO2019169168A1 (en) | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using agathobaculum |
| WO2019178057A1 (en) | 2018-03-12 | 2019-09-19 | Evelo Biosciences, Inc. | Methods of treating cancer using burkholderia |
| WO2019217522A1 (en) * | 2018-05-08 | 2019-11-14 | Mayo Foundation For Medical Education And Research | Methods for treating ovarian cancer |
| US12163129B2 (en) | 2018-06-08 | 2024-12-10 | University Of Massachusetts | Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells |
| GB201816547D0 (en) | 2018-10-10 | 2018-11-28 | Univ London Queen Mary | Oncolytic virus for the treatment of cancer |
| US20220112519A1 (en) * | 2019-02-19 | 2022-04-14 | Board Of Regents, The University Of Texas System | Genetic targeting of cellular or neuronal sub-populations |
| JP2022523779A (ja) | 2019-03-12 | 2022-04-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 癌を処置するための方法および組成物 |
| US12582726B1 (en) | 2019-04-05 | 2026-03-24 | Earli Inc. | Synthetic cancer-specific promoters |
| CA3132338A1 (en) * | 2019-04-05 | 2020-10-08 | David Suhy | Improved methods and compositions for synthetic biomarkers |
| WO2020252257A1 (en) | 2019-06-12 | 2020-12-17 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| WO2021022110A1 (en) | 2019-08-01 | 2021-02-04 | Evelo Biosciences, Inc. | Inducing immune effects using bacteria of the genus bifidobacterium |
| CN115484986A (zh) | 2020-01-06 | 2022-12-16 | 海阳制药 | 用于预防或治疗黄斑变性的含有细胞可渗透的核酸复合物作为活性成分的组合物 |
| CA3167369A1 (en) | 2020-03-04 | 2021-09-10 | Tara YOUNG | Methods and compositions for sensitization of tumor cells to immune therapy |
| WO2021188534A1 (en) * | 2020-03-16 | 2021-09-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for improving heart function and treating heart failure |
| EP4157264A4 (de) | 2020-05-27 | 2024-06-19 | The Regents of the University of California | Zusammensetzungen und verfahren zur transdifferenzierung von zellen |
| WO2022056454A2 (en) | 2020-09-14 | 2022-03-17 | President And Fellows Of Harvard College | Methods and compositions for treating hpv-positive cancers |
| IL301306A (en) | 2020-09-16 | 2023-05-01 | Harvard College | Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy |
| WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
| WO2023182870A1 (ko) * | 2022-03-24 | 2023-09-28 | (주)셀레브레인 | 신규 재조합 벡터 및 이의 용도 |
| KR102632204B1 (ko) * | 2022-03-24 | 2024-02-02 | (주)셀레브레인 | 신규 재조합 벡터 및 이의 용도 |
| WO2025038750A2 (en) | 2023-08-14 | 2025-02-20 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69133617D1 (de) | 1990-04-04 | 2009-07-23 | Novartis Vaccines & Diagnostic | Protease von Hepatitis C Virus |
| US6194140B1 (en) | 1990-04-04 | 2001-02-27 | Chiron Corporation | HCV NS3 protein fragments having helicase activity and improved solubility |
| US6127116A (en) | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| BRPI9908967B1 (pt) | 1998-03-20 | 2017-05-30 | Benitec Australia Ltd | processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta |
| US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
| WO2001068836A2 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| AU2001254563A1 (en) * | 2000-04-21 | 2001-11-12 | Boehringer Ingelheim (Canada) Ltd. | Internal de novo initiation sites of the hcv ns5b polymerase and use thereof |
| EP1383782A1 (de) * | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonukleotidvermittelte inhibierung der replikation des hepatitis--b-virus und des hepatitis-c-virus |
| US6693701B2 (en) * | 2001-05-29 | 2004-02-17 | Ibsen Photonics A/S | Method and apparatus for diffractive transfer of a mask grating |
| AUPR644301A0 (en) * | 2001-07-17 | 2001-08-09 | Unisearch Limited | Method and composition for treatment of cancer |
| WO2003016572A1 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Oligonucleotide therapeutics for treating hepatitis c virus infections |
| AU2002326906C1 (en) | 2001-09-13 | 2009-01-29 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| JP3642573B2 (ja) * | 2001-11-28 | 2005-04-27 | 株式会社東京大学Ｔｌｏ | ｓｉＲＮＡ発現システムおよびこれを用いた機能遺伝子ノックダウン細胞等の生産方法 |
| GB2397062B (en) * | 2002-02-20 | 2005-06-15 | Sirna Therapeutics Inc | RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA) |
| ES2346645T3 (es) * | 2002-03-14 | 2010-10-19 | Commonwealth Scientific And Industrial Research Organisation | Procedimientos y medios de supervision y modulacion del silenciamiento genico. |
| JP2005521393A (ja) * | 2002-03-20 | 2005-07-21 | マサチューセッツ インスティテュート オブ テクノロジー | Ｈｉｖ治療 |
| DE10212892A1 (de) | 2002-03-20 | 2003-10-09 | Basf Plant Science Gmbh | Konstrukte und Verfahren zur Regulation der Genexpression |
| US20040053876A1 (en) * | 2002-03-26 | 2004-03-18 | The Regents Of The University Of Michigan | siRNAs and uses therof |
| US8211455B2 (en) * | 2002-06-19 | 2012-07-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled delivery of a therapeutic agent |
| EP1532248B1 (de) * | 2002-07-26 | 2009-04-01 | Novartis Vaccines and Diagnostics, Inc. | Modifizierte kleine irns moleküle und methoden zu deren anwendung |
| WO2004020605A2 (en) | 2002-08-29 | 2004-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Circular nucleic acid vectors, and methods for making and using the same |
| WO2004078974A1 (ja) * | 2003-01-24 | 2004-09-16 | Tokyo Metropolitan Organization For Medical Research | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
| CN1276976C (zh) | 2003-10-30 | 2006-09-27 | 封江南 | 单一载体编码多个发夹结构小干扰性rna表达系统及其构建方法 |
| ES2366126T3 (es) * | 2004-03-05 | 2011-10-17 | Benitec, Inc. | CASSETTE DE EXPRESIÓN DE PROMOTOR MÚLTIPLE PARA EL SUMINISTRO SIMULTÁNEO DE AGENTES ARNi. |
| KR101246862B1 (ko) | 2004-03-05 | 2013-03-27 | 베니텍 리미티드 | ＲＮＡｉ 제제의 동시 전달을 위한 다중 프로모터 발현카세트 |
-
2005
- 2005-03-04 KR KR1020067020986A patent/KR101246862B1/ko not_active Expired - Fee Related
- 2005-03-04 CN CN201210556628.0A patent/CN103060324B/zh not_active Expired - Fee Related
- 2005-03-04 AU AU2005222084A patent/AU2005222084B2/en not_active Ceased
- 2005-03-04 AT AT05727680T patent/ATE508190T1/de not_active IP Right Cessation
- 2005-03-04 DK DK05727680.0T patent/DK1725660T3/da active
- 2005-03-04 NZ NZ550284A patent/NZ550284A/en not_active IP Right Cessation
- 2005-03-04 EP EP05727680A patent/EP1725660B1/de not_active Expired - Lifetime
- 2005-03-04 CA CA2558771A patent/CA2558771C/en not_active Expired - Fee Related
- 2005-03-04 EP EP11161216.4A patent/EP2363483A3/de not_active Withdrawn
- 2005-03-04 US US11/072,592 patent/US7727970B2/en not_active Expired - Fee Related
- 2005-03-04 WO PCT/US2005/007447 patent/WO2005087926A2/en not_active Ceased
- 2005-03-04 DE DE602005027820T patent/DE602005027820D1/de not_active Expired - Lifetime
- 2005-03-04 KR KR1020127000533A patent/KR101337579B1/ko not_active Expired - Fee Related
- 2005-03-04 JP JP2007502094A patent/JP4763681B2/ja not_active Expired - Fee Related
-
2006
- 2006-09-03 IL IL177862A patent/IL177862A/en not_active IP Right Cessation
-
2010
- 2010-03-12 US US12/723,466 patent/US8283461B2/en not_active Expired - Fee Related
-
2012
- 2012-09-26 US US13/627,644 patent/US8691967B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2558771A1 (en) | 2005-09-22 |
| US20050197313A1 (en) | 2005-09-08 |
| US8691967B2 (en) | 2014-04-08 |
| DE602005027820D1 (de) | 2011-06-16 |
| EP2363483A2 (de) | 2011-09-07 |
| US8283461B2 (en) | 2012-10-09 |
| WO2005087926A3 (en) | 2006-03-16 |
| US20130171726A1 (en) | 2013-07-04 |
| IL177862A (en) | 2014-05-28 |
| AU2005222084B2 (en) | 2010-04-22 |
| CN103060324A (zh) | 2013-04-24 |
| KR20070063470A (ko) | 2007-06-19 |
| CN103060324B (zh) | 2015-04-01 |
| WO2005087926A2 (en) | 2005-09-22 |
| KR101246862B1 (ko) | 2013-03-27 |
| EP1725660A2 (de) | 2006-11-29 |
| JP4763681B2 (ja) | 2011-08-31 |
| KR101337579B1 (ko) | 2013-12-06 |
| EP1725660B1 (de) | 2011-05-04 |
| EP2363483A3 (de) | 2014-07-16 |
| US20110003378A1 (en) | 2011-01-06 |
| JP2007527244A (ja) | 2007-09-27 |
| DK1725660T3 (da) | 2011-08-29 |
| KR20120008094A (ko) | 2012-01-25 |
| US7727970B2 (en) | 2010-06-01 |
| CA2558771C (en) | 2013-01-08 |
| IL177862A0 (en) | 2006-12-31 |
| NZ550284A (en) | 2009-04-30 |
| AU2005222084A1 (en) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005027820D1 (de) | Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien | |
| CY1118007T1 (el) | Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων | |
| CY1115786T1 (el) | Μεσο φυλαξης για κυτταρα | |
| TW200806317A (en) | Methods for reducing protein aggregation | |
| WO2007044323A3 (en) | Fusion proteins for blood-brain barrier delivery | |
| CR20110477A (es) | Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38 | |
| EA201001628A1 (ru) | Модифицированные полипептиды фактора vii и их применение | |
| NO20071127L (no) | Triazoloftalaziner | |
| CR20110230A (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
| HRP20150828T8 (hr) | Kompozicije i postupci in vitro i in vivo ciljanog oslobađanja lijeka u stanicama sisavaca, preko intaktnih mini-stanica izvedenih iz bakterija | |
| EP2061907A4 (de) | Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll) | |
| EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
| ATE375518T1 (de) | Diagnoseverfahren für erkrankungen unter verwendung von copeptin | |
| DK1874341T3 (da) | Erythrocytter, der indeholder arginin deiminase | |
| CY1119509T1 (el) | Συνθεσεις και μεθοδοι για ρυθμιστες αποπτωσης | |
| DE602004011334D1 (de) | Rüttler für Zellkulturklimaschrank | |
| EP2195331A4 (de) | Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren | |
| CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
| MX2007008136A (es) | Metodo para invertir la resistencia multiple en celulas animales. | |
| BR0313588A (pt) | Métodos para o tratamento da demência com base em apo e genótipo | |
| EA201071031A1 (ru) | Носители никорандила с повышенной стабильностью | |
| FR2872431B1 (fr) | Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire | |
| CL2009000257A1 (es) | Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico. | |
| AR059193A1 (es) | Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias | |
| EA200870058A1 (ru) | Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |